129999-60-6

Usage

Uses

Used in Pharmaceutical Industry:
N-AEP is utilized as a synthetic intermediate for the production of pharmaceuticals and organic compounds. Its unique chemical structure allows it to be a key component in the synthesis of various medicinal agents.
Used as a Chelating Agent:
N-AEP serves as an effective chelating agent, capable of binding to metal ions. This property makes it useful in various applications where metal ion sequestration is required, such as in the purification of water or in the stabilization of chemical reactions.
Used in Corrosion Inhibitors:
In the field of material protection, N-AEP is incorporated into corrosion inhibitors. Its ability to form complexes with metal surfaces helps to prevent or reduce the corrosion of metals, thus extending the service life of various industrial equipment and structures.
Used in Anti-inflammatory and Analgesic Applications:
N-AEP has been studied for its potential as an anti-inflammatory and analgesic agent. Its preclinical models have demonstrated promising results, suggesting that it could be a valuable asset in the development of new treatments for pain and inflammation.
Used in Addiction Treatment:
Furthermore, N-AEP has been investigated for its potential use in the treatment of alcohol and drug addiction. Its unique properties may offer new avenues for managing and treating these challenging conditions, providing hope for those affected by addiction.

InChI:InChI=1/C7H16N2O/c8-3-6-9-4-1-7(10)2-5-9/h7,10H,1-6,8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 78503-67-0 4-hydroxypiperidin-1-ylacetonitrile 

Downstream Products

• 857637-31-1 2-(4-chloropiperidin-1-yl)ethanamine 
• 948895-18-9 2,6-dichloro-N-[2-(4-hydroxypiperidin-1-yl)ethyl]benzamide 
• 948896-01-3 N-[2-(4-hydroxypiperidin-1-yl)ethyl]benzenesulfonamide 
• 1226860-98-5 1-[2-({6-[(5-Methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)-methyl]pyridin-3-yl}amino)ethyl]piperidin-4-ol 
• 1226861-07-9 N-[2-(4-Hydroxypiperidin-1-yl)ethyl]-5-[(5-methyl-3-{3-[4-(trifluoromethoxy)phenyl]-1,2,4-oxadiazol-5-yl}-1H-pyrazol-1-yl)methyl]pyridine-2-carboxamide 
• 1415397-43-1 C₂₂H₃₁N₅O₃S 
• 948896-03-5 N-[2-(4-oxopiperidin-1-yl)ethyl]benzenesulfonamide 
• 948895-19-0 2,6-dichloro-N-[2-(4-oxopiperidin-1-yl)ethyl]benzamide 
• 948896-05-7 N-[2-(4-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}piperidin-1-yl)ethyl]benzenesulfonamide 

Relevant academic research and scientific papers

PKM2 MODULATORS AND METHODS FOR THEIR USE

Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein

PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS

The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists.

ANTHARQUINONE COMPOUNDS AS ANTI CANCER COMPOUNDS

Anthraquinone compounds of the general formula (I) or a salt thereof (Formula I) in which R1 to R4 are each selected from the group consisting of H, C1-4 alkyl, X1, -NHR0N (R5)2 in which R0 is a C1-12 alkanediyl and each R5 is H or optionally substituted C1-4 alkyl, and a group of formula (II) in which at least one of R6,R7 and R8 is selected from X2 , and X2 substituted C1-4 alkyl and any others are H or C1-4 alkyl; R9 is selected from H, C1-4 alkyl, X2 and X2 substituted C1-4 alkyl; m is 0 or 1; n is 1 or 2; X1 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; and X2 is a halogen atom, a hydroxyl group, a C1-6 alkoxyl group, an aryloxy group or an acyloxy group; provided that at least one of R1 to R4 is a group of formula (II). The N-oxides are useful prodrugs which are selectively bioreduced in hypoxic tumours to the corresponding cyclic amine derivatives. The amine compounds are cytotoxic and may be used as alkylating agents having topoisomerase II inhibiting activities in cancer therapy.

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells

A novel series of 1,4-disubstituted aminoanthraquinones were prepared by ipso-displacement of 1,4-difluoro-5,8-dihydroxyanthraquinones by hydroxylated piperidinyl- or pyrrolidinylalkyl-amino side chains. One aminoanthraquinone (13) was further derivatized to a chloropropyl-amino analogue by treatment with triphenylphosphine-carbon tetrachloride. The compounds were evaluated in the A2780 ovarian cancer cell line and its cisplatin-resistant variants (A2780/cp70 and A2780/MCP1). The novel anthraquinones were shown to possess up to 5-fold increased potency against the cisplatin-resistant cells compared to the wild-type cells. Growth curve analysis of the hydroxyethylaminoanthraquinone 8 in the osteosarcoma cell line U-2 OS showed that the cell cycle is not frozen, rather there is a late cell cycle arrest consistent with the action of a DNA-damaging topoisomerase II inhibitor. Accumulative apoptotic events, using time lapse photography, indicate that 8 is capable of fully engaging cell cycle arrest pathways in G2 in the absence of early apoptotic commitment. 8 and its chloropropyl analogue 13 retained significant activity against human A2780/cp70 xenografted tumors in mice.